A custom VHH discovery service develops and evaluates single-domain antibody candidates against a target selected for your research or product program. A typical project moves from target and assay planning through immunization or another agreed discovery approach, candidate screening, sequence analysis, and delivery of documented VHH leads. For veterinary medicine, the brief should also define the intended animal species, sample matrix, and use case, because those choices affect how candidates should be screened. Before starting, agree with your provider on the workflow, acceptance criteria, deliverables, timeline assumptions, and responsibilities in writing.
This guide is for veterinary diagnostics developers, animal-health researchers, biotechnology teams, and procurement professionals evaluating a custom VHH discovery project. It is relevant whether you are investigating a pathogen, toxin, biomarker, or another veterinary target. It can also help teams compare suppliers and prepare a request for proposal. It is not a substitute for a project-specific scientific, biosafety, or regulatory assessment.
VHHs are single-domain antibody fragments associated with camelid heavy-chain antibodies. In a custom discovery project, the provider works with the client to generate and identify VHH candidates that bind a specified target under defined screening conditions. Discovery does not by itself establish diagnostic validity, therapeutic suitability, manufacturability, or regulatory readiness. Those outcomes require application-specific follow-up work.
Depending on the provider’s offering and project design, discovery may use an immunized-animal immune repertoire, a naïve or synthetic library, or another agreed source of candidate diversity. The appropriate route depends on factors such as target availability, desired recognition properties, schedule, and the project’s ethical and operational constraints. Ask the supplier to explain the proposed route and what evidence will be generated at each stage. Do not assume every provider offers every route.
The target can be supplied as purified protein, a prepared construct, cells expressing a membrane target, or another suitable presentation format. The choice should reflect the form encountered in the intended veterinary application. For example, a candidate screened only against an isolated protein may not necessarily recognize the target in a complex sample or on a cell surface. Discuss target conformation, species variants, and relevant negative or counter-screen targets before work begins.
Start by stating whether the goal is a research reagent, an assay component, a diagnostic candidate, or an early therapeutic research lead. Identify the target species, expected sample types, and any known homologs or variants that could affect specificity. Translate the use case into measurable screening questions, such as binding to a target form or avoiding a named off-target. Agree on what constitutes a candidate worth advancing, rather than relying on a general promise of “high affinity.”
Share available target information, including sequence, construct boundaries, tags, expression system, purity data, and handling conditions where available. The provider should review whether the material and presentation are suitable for the proposed discovery and screening plan. If the target is unstable, difficult to express, or dependent on a particular conformation, discuss alternatives before committing to a workflow. For veterinary targets, clarify whether the sequence represents one species, multiple species, or a specific strain or variant.
Use project figures as planning examples, not universal acceptance criteria. For instance, an intake worksheet might record 0.5 mg of available antigen, a concentration of 1 mg/mL, and storage at −80 °C; the provider should confirm whether those quantities and conditions fit the actual target and protocol. These example values do not establish a required amount, ideal concentration, or validated storage condition. Ask for written sample requirements before shipping any material.
After the discovery source and target presentation are agreed, the provider carries out the agreed generation and screening activities. Screening may include binding assays and additional tests selected to address the project’s specificity or application needs. Ask which assay formats will be used, what controls are included, and whether screening is performed against the final target form or only a surrogate. The methods and criteria should be documented so results can be interpreted in context.
NBbiolab Product Page
Promising candidates are typically characterized further before a lead list is finalized. Depending on scope, this can include sequence identification, repeat binding assessment, comparative ranking, or evaluation in an application-relevant assay. Request clear definitions for terms such as “hit,” “confirmed binder,” and “lead,” because suppliers may use different thresholds. A binding result alone should not be treated as proof of performance in a veterinary diagnostic or treatment setting.
At project close, the provider transfers the materials and documentation specified in the contract. These may include VHH amino-acid or nucleotide sequences, purified candidate material, expression constructs, screening results, and a summary of methods or conditions. Confirm file formats, material quantities, ownership and use rights, and any restrictions on redistribution or commercial use. If further optimization or scale-up is needed, define it as a separate scope or an explicitly included project phase.
A deliverable list should distinguish data, physical materials, and rights. For data, specify whether you expect raw results, analyzed results, assay protocols, sequences, and candidate-ranking rationale. For physical outputs, state the form and quantity of VHH material or genetic constructs, along with any agreed quality checks. For rights, document ownership, permitted applications, confidentiality, and publication or disclosure terms.
| Deliverable area | Questions to resolve |
|---|---|
| Candidate identity | Will amino-acid and nucleotide sequences be provided, and in what format? |
| Experimental evidence | Which assays, controls, and results are included in the final report? |
| Physical materials | Are purified VHHs, plasmids, or other materials included, and in what quantities? |
| Project rights | Who owns the resulting sequences and materials, and what use is permitted? |
| Further development | Are optimization, reformatting, or production services included or quoted separately? |
For veterinary diagnostics, prioritize screening conditions that reflect the intended sample and assay format. A candidate that binds purified antigen may still require evaluation for matrix interference, cross-reactivity, and performance across relevant animal species or pathogen variants. For research reagents, reproducibility and target specificity may be more important than immediate performance in a commercial assay. For therapeutic research, additional considerations such as species compatibility, developability, safety, and regulatory strategy require specialist review beyond discovery.
Ask the provider to distinguish discovery-stage evidence from later validation. If the intended product will be used with serum, milk, tissue, or another sample type, describe that matrix early and determine whether matrix testing is in scope. For multi-species use, identify the species and target variants that matter rather than assuming cross-species recognition. This helps prevent a technically successful discovery from being evaluated against the wrong product requirement.
Custom project pricing depends on factors such as the discovery route, target complexity, number of targets, screening depth, and requested deliverables. There is no universal minimum order quantity or standard price that applies to every VHH discovery project. Lead time also depends on the agreed workflow, material readiness, and decision points; request a supplier estimate tied to a written scope rather than relying on a generic duration. Ask which events start the schedule and how delays, additional screening, or replacement target material are handled.
NBbiolab can discuss a custom VHH discovery scope with veterinary medicine teams, including target information, intended application, screening priorities, and expected outputs. Provide the target details and project goals when requesting a proposal so the workflow and deliverables can be assessed against your requirements. Confirm the specific services, sample inputs, schedule, and commercial terms directly with the project team before initiating work.
A custom VHH discovery service is best planned as a defined sequence of target review, candidate generation, application-relevant screening, sequence confirmation, and documented transfer. The strongest project briefs connect the veterinary use case to target format, sample context, screening criteria, deliverables, and rights. Before selecting a supplier, compare the proposed methods and acceptance criteria, not just headline cost or estimated duration. Your next step is to prepare a concise target dossier and request a written scope that clearly separates discovery outputs from downstream validation or development.
For more Custom VHH Discovery Serviceinformation, please contact us. We will provide professional answers.